

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**愛 帝 宮 母 嬰 健 康 股 份 有 限 公 司**

**AIDIGONG MATERNAL & CHILD HEALTH LIMITED**

*(Incorporated in Bermuda with limited liability)*

**(Stock code: 286)**

## **QUARTERLY UPDATE ON RESUMPTION PROGRESS**

This announcement is made by Aidigong Maternal & Child Health Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 and 13.24A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

References are made to the announcement of the Company dated 17 January, 5, 13, 18 March, 2, 30 April and 20 August 2025, (collectively, the “**Announcements**”) in relation to, among others, (i) the guidance for the resumption of trading in the Shares set by the Stock Exchange (the “**Resumption Guidance**”); (ii) quarterly update on the resumption of trading of the shares of the Company; and (iii) the legal proceedings in relation to, among others, the alleged debt due to Shenzhen Aidigong and Ms. Zhu Yufei’s disagreement with Guangdong Wanjia regarding the exercise of shareholders rights in Shenzhen Aidigong. Unless otherwise defined or the context otherwise requires, capitalised terms in this announcement shall have the same meanings as those defined in the Announcements.

## **BUSINESS OPERATIONS**

The Group has continued business operations notwithstanding the suspension of trading in the Shares on the Stock Exchange.

## **UPDATE ON THE 2024 ANNUAL RESULTS AND ANNUAL REPORT**

The Company is still in the progress of obtaining the necessary financial information on Shenzhen Aidigong and its subsidiaries for the Auditors to conduct the annual audit and prepare the 2024 Annual Results. The expected dates of the publication of the 2024 Annual Results and the annual report for the year ended 31 December 2024 will need to be further agreed with the Auditors, and a separate announcement will be made by the Company as and when appropriate.

## **UPDATE ON PROGRESS OF RESUMPTION**

The Company remains committed to working towards the resumption of trading in the Shares. However, as the Company has difficulties in obtaining the relevant documents of Shenzhen Aidigong as disclosed in the Announcements, the Company has yet to agree on the scope of the independent forensic investigation into the Matters and the independent internal control review. The Company has been actively communicating with independent forensic investigators and internal control consultants regarding the timeline for the fulfilment of the Resumption Guidance upon the commencement of their work. In addition, the Company continued to be in discussions with professional advisers of the Group to explore and consider opportunities available to the Company in formulating a comprehensive and viable resumption proposal to address matters set out in the Resumption Guidance.

Meanwhile, the Group has been actively pursuing legal actions against Ms. Zhu Yufei as well as defending against the claims made by Ms. Zhu Yufei and other relevant entities as disclosed in the Announcements to protect the interests of the Group. In relation to the SZA Arbitration regarding the Debt, which Ms. Zhu Yufei might have initiated in the name of Shenzhen Aidigong without due authorisation from the Group, the arbitration court has suspended the proceedings pending the conclusion of the lawsuit in relation to the validity of the Resolution as disclosed in the announcement of the Company dated 17 January 2025. For the Arbitration regarding the exercise of shareholders rights in Shenzhen Aidigong initiated by Ms. Zhu Yufei, the first arbitration hearing has been scheduled to be held on 22 August 2025. The Company will issue further announcement in this regard if and when appropriate.

The Company is also reviewing the composition of the Board and will take appropriate steps to fulfill the requirements under Rules 3.10(1), 3.10A and 3.21 of the Listing Rules.

The Company has been working and will continue to work closely with all relevant parties towards the resumption of trading in its shares and will keep the Company's shareholders and potential investors informed of the progress on the fulfillment of the Resumption Guidance.

## **CONTINUED SUSPENSION OF TRADING**

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended since 9:54 a.m. on 21 February 2025 and will remain suspended until further notice.

**Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Aidigong Maternal & Child Health Limited**  
**Wong Wing Cheung**  
*Company Secretary*

Hong Kong, 20 August 2025

*As at the date of this announcement, the Board comprises Mr. Huang Wenhua, Mr. Lin Jiang, Mr. Li Runping and Ms. Meng Lijia as executive Directors; Mr. Chu Pui Ki Dickson and Mr. Wang Bin as independent non-executive Directors.*